INTRODUCTION
Chronic kidney disease (CKD) is characterized by a reduced glomerular filtration rate and progressive impaired renal function. It has become a global public health issue with an estimated prevalence of 8%–16% (Jha et al., ). Worldwide, diabetes mellitus, hypertension, and glomerulonephritis are the common causes of CKD. Patients with CKD experience several complications including increased blood pressure, anemia, acute kidney injury, cardiovascular mortality, and accumulation of high levels of uremic toxins.
More than 2,000 species of commensal bacteria live in the intestinal tract in a natural balance. They constitute a dynamic and symbiotic ecosystem that interacts with the host metabolism (Bourlioux, Koletzko, Guarner, & Braesco, ; Dunne, ; Hooper & Gordon, ; Iannitti & Palmieri, ). A large number of recent studies demonstrated the association of gut microbiota with many diseases including obesity, type 2 diabetes, and nonalcoholic fatty liver disease (Abu‐Shanab & Quigley, ; Qin et al., ; Ridaura et al., ). Recent studies have suggested that the gut microbiota is one of the pathogenic factors in kidney disease (Anders, Andersen, & Stecher, ). Vaziri and his colleagues used the 16S rRNA gene PhyloChip technique to demonstrate that uremia profoundly altered intestinal microbial flora (Vaziri, Wong, et al., ). Furthermore, some studies investigated the potential of intestinal microbial flora as microbial biomarkers for the noninvasive diagnosis and selection of an appropriate personalized treatment (Pascal et al., ; Sommer et al., ). However, it remains unclear which microbial biomarkers are more appropriate for CKD.
Therefore, this study was performed to explore the differences in gut microbiota between patients with CKD and healthy controls (HC) and further search more appropriate microbial biomarkers associated with CKD.
MATERIAL AND METHODS
Study population
This study included 49 patients with CKD (37 males and 12 females aged 54 ± 14 years) and 24 HC (16 males and eight females aged 56 ± 9 years) (age, Student t test, p = 0.303). All enrolled participants signed the informed consent. The study was reviewed and approved by the Medical Ethics Committee of Taian City Central Hospital, Taian, China. Of the 49 patients with CKD, 13 underwent hemodialysis and the remaining were never treated with dialysis. Patients with malignancy, pregnancy, acute or chronic infections, chronic inflammatory bowel disease, and celiac disease were excluded. All participants in this study did not take any antibiotics, probiotics, prebiotics, or symbiotics during the 3 months before fecal samples were collected. Stool samples from enrolled participants were collected in a sterile plastic cup and stored at −80°C for further microbiome analysis.
Microbiota analysis
The V3–V4 region of the 16S rRNA gene was amplified and sequenced on the Illumina Hiseq System (PE250) to profile the microbial composition of fecal samples. The forward primer was 341F: CCTAYGGGRBGCASCAG, and the reverse primer was 806R: GGACTACHVGGGTWTCTAAT. All polymerase chain reactions were performed in 20‐μl reaction mixtures with 4 μl of 5 × FastPfu Buffer, 2 μl of 2.5 mM dNTPs, 0.5 μM forward and reverse primers, 0.4 μl of FastPfu Polymerase, and 10 ng template DNA. Thermal cycling consisted of initial denaturation at 95°C for 5 min, 27 cycles of denaturation at 99°C for 30 s, annealing at 55°C for 30 s, elongation at 72°C for 45 s, and maintenance at 72°C for 10 min. The library was constructed and sequenced on an Illumina HiSeq platform. Sequences were grouped into operational taxonomic units (OTUs) using the Usearch (version 7.1
The ability of the microbial markers to differentiate between HC and CKD was evaluated using the area under the receiver operating characteristic (ROC) curve. The phylotypes detected in hemodialysis samples and HC group were discovered by evaluating the data from high‐throughput sequencing.
Statistical analysis
The statistical analysis of quantitative data and ROC was conducted with the Student t test using SPSS 16.0. A p value less than 0.05 was considered statistically significant.
RESULTS
The gut microbiota of patients with CKD and HC were investigated using the high‐throughput sequencing of the V3–V4 region of the 16S rDNA gene, and a total of 2,754,607 reads were sequenced.
Bacterial microbiota composition
In this study, most of the bacteria of fecal samples collected from both CKD and HC groups belonged to the phyla Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria (98.2% and 98.46%, respectively) (Figure a,b). The relative abundance of the dominant main phyla Firmicutes, Bacteroidetes, and Proteobacteria between CKD and HC groups significantly changed. The CKD group had a significantly higher abundance of Bacteroidetes and Proteobacteria and lower abundance of Firmicutes compared with the HC group (Student t test, p = 0.002, 0.03, and 0.000, respectively). The clustering analysis also showed that the CKD group differed from the HC group at the phyla level (Figure c). The Venn diagram represented shared/unique OTUs in the gut microbiota of the CKD and HC groups (Figure d).
Taxonomic analysis of gut microbiota from 16S rRNA sequencing. (a) Composition of gut microbiota (phylum) of HC. (b) Composition of gut microbiota (phylum) of CKD. (c) Relative abundance of microbial community at the phylum level in fecal samples collected from both the CKD and HC groups. (d) Venn diagram of fecal microbiota at the OTU level. Each ellipse represents one sample. Red represents HC, whereas green represents CKD
Bacterial microbiota diversity analysis
The beta diversity of the samples was evaluated using PCA based on the Euclidean distance to investigate the differences in the structure of gut microbiota (Figure a). The result revealed that the gut microbiota of patients with CKD were distinct from those of the HC with the first two principal component scores 15.16% and 12.24%, respectively. NMDS based on UniFrac distance also showed a separation trend of the HC and CKD groups at the OTU level (Figure b).
(a) Visualization of the PCA analysis based on the Euclidean distance. (b) Nonmetric multidimensional scaling (NMDS) plot of microbial communities, based on the OUT level, derived from fecal samples of HC (red) and patients with CKD (blue)
Differences in gut microbiota between the CKD and HC groups
The differences in gut microbiota between the CKD and HC groups were determined using the Linear discriminant analysis Effect Size (LEfSe). The cladogram generated from the LEfSe analysis showed the most differentially abundant taxa enriched in microbiota from the CKD or HC group (Figure a). The histogram indicated that a difference of 49 phylotypes was observed between the CKD and HC groups (Figure b). A total of 31 phylotypes were different at the genus level, and they might serve as biomarkers to differentiate between CKD and HC populations. Among the 31 phylotypes, 12 were more abundant in the CKD group, including Bacteroides, Escherichia_Shigella, Parabacteroides, Ruminococcus_ gnavus, Ruminococcus torques, Weissella, Flavonifractor, Ruminiclostridium5, Sellimonas, Erysipelatoclostridium, Eggerthella, and Clostridium_innocuum. Furthermore, 19 phylotypes were more abundant in the HC group, including Dialister, Eubacterium rectale, Carnobacterium, Lachnospira, Subdoligranulum, Eubacterium_coprostanoligenes, Coprococcus2, Roseburia, RuminococcaceaeUCG_009, RuminococcaceaeNK4A214, LachnospiraceaeFCS020, Ruminococcus1, Romboutsia, Butyricicoccus, Collinsella, RuminococcaceaeUCG_003, Eubacterium_halliigroup, Tyzzerella3, and LachnospiraceaeUCG_001.
(a) Cladogram showing the most differentially abundant taxa identified by LEfSe. Red indicates clades enriched in the HC group, whereas green indicate clades enriched in the CKD group. (b) Comparisons of gut bacteria between the HC and CKD groups. The histogram shows the LDA score computed for genera differentially abundant between groups and identified using LEfSe
Comparison of microbial biomarkers
ROC curves of five phylotypes with the five highest LDA scores at the genus level in the HC and CKD groups and their area under the ROC curve (AUC) values were obtained to explore the ability of the gut microbiome to differentiate between the HC and CKD groups. Out of the five phylotypes tested, Lachnospira achieved the best performance in the HC group (AUC = 0.813; 95% CI: 0.713–0.912; p = 0.000) (Figure a) and Ruminococcus_gnavus was the best in the CKD group (AUC = 0.764; 95% CI: 0.656–0.873; p = 0.000) (Figure b).
ROC curves for microbial biomarkers. (a) ROC curves of five phylotypes with the highest LDA score at the genus level in the HC group. (b) ROC curves of five phylotypes with the highest LDA score at the genus level in the CKD group. A higher curve generally indicates a better method. AUC statistic summarizes the trade‐offs across the varied sensitivity/specificity range
Microbial markers associated with the progression of CKD and hemodialysis
The data from high‐throughput sequencing were analyzed to explore microbial species associated with the progression of CKD and hemodialysis. At the genus level, the genera Holdemanella, Megamonas, and Prevotella2 were not detected in the HD samples, and the rate of their detection decreased in the CKD group compared with the HC group. The genera Dielma and Scardovia were not detected in all the HC samples (Table ).
Detection rate of bacteria at the genus levelBacteria | HD | Non‐HD | HC |
Holdemanella | 0% | 11.76% | 33.33% |
Megamonas | 0% | 14.71% | 45.83% |
Prevotella2 | 0% | 5.88% | 29.17% |
Dielma | 31% | 29.41% | 0.00% |
Scardovia | 23% | 2.94% | 0.00% |
DISCUSSION
This study used the high‐throughput sequencing of the fecal microbiota of patients with CKD and HC to investigate the alteration of intestinal microbiota in patients with CKD. Significant differences in the composition of gut microbiota were found between the CKD and HC groups. At the phylum level, a significantly increased prevalence of Bacteroidetes and Proteobacteria and a reduced prevalence of Firmicutes were found in patients with CKD. Gut microbiota are vital in the progression of CKD. The fermentation of amino acids tyrosine and tryptophan obtained from food by intestinal microbiota generates p‐cresol and indole, respectively, which are further metabolized to generate p‐cresyl sulfate and p‐indoxyl sulfate in the liver after absorption. These toxins are eliminated mainly by tubular secretion in the kidneys. Their increased concentration is associated with renal impairment and advancing CKD (Poesen, Meijers, & Evenepoel, ).
The relationship between the human microbiome and kidney disease is bidirectional. CKD also affects the structure of gut microbiota and contributes to symbiosis. Studies on uremic rats showed marked azotemia, systemic oxidative stress, and marked depletion of the key protein constituents of the epithelial tight junction (claudin‐1, occludin, and ZO1) in the stomach, jejunum, and ileum (Vaziri, Yuan, Nazertehrani, Ni, & Liu, ). Many factors are associated with CKD, including frequent use of antibiotics (Jakobsson et al., ), decreased consumption of dietary fibers (Kalantar‐Zadeh, Kopple, Deepak, Block, & Block, ), metabolic acidosis, slow colonic transit, intestinal wall edema, volume overload with intestinal wall congestion, and oral iron intake (Fouque et al., ; Nakao, ; ). Many of these factors lead to the translocation of bacteria and microbial dysbiosis. Elevated levels of gut fluid urea and uric acid and reduced levels of fiber‐derived short‐chain fatty acids, which contribute to uremia‐induced microbial dysbiosis (Wong et al., ), may be the causal factors for microbial dysbiosis in patients with CKD. When the kidney function is insufficient, urea is secreted into the gastrointestinal tract, hydrolyzed by the expansion of urease‐possessing bacteria, and results in the production of large quantities of ammonia, which contributes to systemic inflammation by disrupting the gut epithelial tight junction (Kang, ; Vaziri, Duresmith, Miller, & Mirahmadi, ; Vaziri, Yuan, & Norris, ; Wong et al., ). In addition, the intestinal dysbiosis of microbiota may be due to iatrogenic causes. Hemodialysis can contribute to recurrent regional ischemia and systemic circulatory stress, which may also damage the mechanical barrier of the gut (Ding & Li, ).
At the genus level, 12 phylotypes were overrepresented in the CKD group and 19 in the HC group. These 31 phylotypes might serve as biomarkers to differentiate between CKD and HC populations. Furthermore, the ability of the gut microbiome with a higher LDA score to differentiate between the HC and CKD groups was assessed. It was found that Lachnospira and Ruminococcus_gnavus achieved the best performance, respectively, in the two groups. Previous studies showed that the decrease in the abundance of genus Lachnospira in the gut microbiome was associated with many diseases. Stiemsma et al. () reported that the abundance of genus Lachnospira (L) decreased in children with asthma, and opposing shifts in the relative abundance of Lachnospira and Clostridium neonatale (C) in the first 3 months of life were associated with preschool‐age asthma, and the L/C ratio might serve as a potential early‐life biomarker to predict asthma development. Wang et al. () found a significant loss of Lachnospira in pediatric patients with Crohn's disease prior to infliximab treatment. In the present study, the relative abundance of Ruminococcus_gnavus was higher in the CKD group. A study reported that the high consumption of red meat, which increased the risk of colorectal cancer, lowered the abundance of Ruminococcus_gnavus (Le Leu et al., ).
In addition, this novel study found that Holdemanella, Megamonas, Prevotella2, Dielma, and Scardovia, which had some association between the detection rate and advancing CKD, had the potential to serve as indicators of the progression of CKD and HD. Moreover, the five phylotypes were used to study the mechanism of interaction between intestinal flora and CKD. Stein () reported that the prevalence of Prevotella significantly reduced in mice with renal failure, which was in line with the findings of the present study. Holdemanella biformis was associated with an unhealthy fasting serum lipid profile (Brahe et al., ). Megamonas had a higher proportion in samples with obesity (Chiu et al., ). Some reports showed that the prevalence of Megamonas significantly increased in healthy individuals compared with diseased individuals (Jun et al., ; Suchodolski et al., ). Dielma fastidiosa was reported in the human gut (Ramasamy, Lagier, Nguyen, Raoult, & Fournier, ). The relative abundance of Scardovia was significantly higher in the salivary samples in the group with caries (Zhou et al., ). Scardovia wiggsiae was associated with the elevated sugar intake (Keller, Kressirer, Belstrøm, Twetman, & Tanner, ).
Several studies have shown a difference in gut microbiota between patients with ESRD and normal controls (Vaziri, Wong, et al., ; Xu et al., ). Improving CKD‐induced dysbiosis can act as a promising targeted treatment in patients with CKD. Recent studies have demonstrated the favorable effect of dietary amylose supplementation on CKD progression and dysbiosis in rats and humans with CKD (Kieffer et al., ; Tayebi Khosroshahi et al., ; Vaziri et al., ). The differential gut microbiota has the potential to guide noninvasive diagnosis and targeted interventions. Given that many factors are associated with the diagnosis of gut microbiota, the biomarker is not a single bacterium but a set of bacteria. The present study found associated phylotypes by analyzing data from the high‐throughput sequencing of the 16S rRNA gene, but the reliability of these bacteria as biomarkers needs to be explored further. Hence, large‐scale prospective studies with extensive sample panels should be conducted to develop more reliable microbiome biomarkers.
ACKNOWLEDGMENTS
This work was financially supported by the National Natural Science Foundation of China (Nos. 31671468), the Shandong Provincial Natural Science Foundation of China (Nos. ZR2016HM15). We express our warm thanks to MedSci for the professional linguistic revision for us.
CONFLICT OF INTEREST
The authors declare no conflicts of interest.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
The present study aimed to determine the differences in gut microbiota between patients with chronic kidney disease (
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Medical Research & Laboratory Diagnostic Center, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong, China; The Department of Clinical Laboratory, Taian City Central Hospital, Taian, Shandong, China
2 Medical Research & Laboratory Diagnostic Center, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong, China
3 The Department of Clinical Laboratory, Taian City Central Hospital, Taian, Shandong, China
4 The Department of Nephrology, Taian City Central Hospital, Taian, Shandong, China